person · Reporting owner

Malik Rajiv

Disclosed activity across 2 companies

Tapewire entity: 82193
SEC CIK: 0001388111

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Viatris IncVTRS · Entity 3277	Director	March 06, 2025	March 10, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Viatris Inc

Report date March 06, 2025 · Filed March 10, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	23,660	Reported balance After 2025-03-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-03-06 · Grant · Acquired 23,660 · Balance 23,660 F1: As previously disclosed on October 20, 2023, the reporting person informed Viatris Inc. ("Viatris") of his intention to retire from his executive role with Viatris effective as of April 1, 2024 and agreed to remain a member of Viatris' Board of Directors. As a non-employee director, the reporting person is eligible to participate in Viatris' non-employee director compensation program. Represents restricted stock units (RSUs) granted for such service, consistent with the grants provided to Viatris' other non-employee directors. F2: Each RSU represents the right to receive one share of common stock of Viatris. These RSUs will vest on March 6, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: As previously disclosed on October 20, 2023, the reporting person informed Viatris Inc. ("Viatris") of his intention to retire from his executive role with Viatris effective as of April 1, 2024 and agreed to remain a member of Viatris' Board of Directors. As a non-employee director, the reporting person is eligible to participate in Viatris' non-employee director compensation program. Represents restricted stock units (RSUs) granted for such service, consistent with the grants provided to Viatris' other non-employee directors.

F2: Each RSU represents the right to receive one share of common stock of Viatris. These RSUs will vest on March 6, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Mylan II B.V.

Report date November 16, 2020 · Filed November 18, 2020

Section 16 reporting ended · disclosed 2020-11-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	0	Reported balance After 2020-11-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-11-16 · Disposition to issuer · Disposed 459,699 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2: 28,546 ordinary shares were returned to the reporting person's direct beneficial ownership on November 10, 2020 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 100,000 ordinary shares on October 23, 2018 and 161,635 ordinary shares were returned to the reporting person's direct beneficial ownership on November 11, 2020 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 250,000 ordinary shares on September 18, 2019. F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Grantor Retained Annuity Trust	0	Reported balance After 2020-11-16 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-11-16 · Disposition to issuer · Disposed 88,365 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.
Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $55.84 · Expires 2024-03-05	Direct	0	Reported balance After 2020-11-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-16 · Disposition to issuer · Disposed 34,389 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F5: These options vested on March 5, 2017.
Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $50.66 · Expires 2025-11-17	Direct	0	Reported balance After 2020-11-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-16 · Disposition to issuer · Disposed 41,637 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F6: These options vested on March 4, 2018.
Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $46.27 · Expires 2026-02-17	Direct	0	Reported balance After 2020-11-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-16 · Disposition to issuer · Disposed 50,168 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F7: These options vested on February 17, 2019.
Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $45.18 · Expires 2027-03-03	Direct	0	Reported balance After 2020-11-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-16 · Disposition to issuer · Disposed 65,574 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F8: These options vested on March 3, 2020.
Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $40.97 · Expires 2028-03-02	Direct	0	Reported balance After 2020-11-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-11-16 · Disposition to issuer · Disposed 71,600 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F9: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021.
Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $27.45 · Expires 2029-03-01	Direct	0	Reported balance After 2020-11-16 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-11-16 · Disposition to issuer · Disposed 60,053 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F14: 20,018 of these options vested on March 2, 2020, 20,017 will vest on March 2, 2021 and 20,018 will vest on March 2, 2022.
Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2030-03-02	Direct	0	Reported balance After 2020-11-16 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2020-11-16 · Disposition to issuer · Disposed 84,871 · Balance 0 F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F17: 28,291 of these options will vest on March 2, 2021 and 28,290 will vest on each of March 2, 2022 and March 2, 2023.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2020-11-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-11-16 · Disposition to issuer · Disposed 14,645 · Balance 0 F9: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. F10: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F11: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2020-11-16 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-11-16 · Disposition to issuer · Disposed 67,031 · Balance 0 F9: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. F10: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F15: Each RSU represents the right to receive one ordinary share of Mylan. 33,515 of the RSUs will vest on March 2, 2021 and 33,516 will vest on March 2, 2022.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2020-11-16 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2020-11-16 · Disposition to issuer · Disposed 157,895 · Balance 0 F9: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. F10: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F18: Each RSU represents the right to receive one ordinary share of Mylan. 52,632 of the RSUs will vest on March 2, 2021, 52,631 will vest on March 2, 2022 and 52,632 will vest on March 2, 2023.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	73,225	Reported balance After 2020-11-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-11-16 · Grant · Acquired 73,225 · Balance 73,225 F12: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2020-11-16 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-11-16 · Disposition to issuer · Disposed 73,225 · Balance 0 F12: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F13: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	125,684	Reported balance After 2020-11-16 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2020-11-16 · Grant · Acquired 125,684 · Balance 125,684 F16: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2020-11-16 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2020-11-16 · Disposition to issuer · Disposed 125,684 · Balance 0 F12: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F13: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination. F16: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	197,369	Reported balance After 2020-11-16 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2020-11-16 · Grant · Acquired 197,369 · Balance 197,369 F19: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2020-11-16 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2020-11-16 · Disposition to issuer · Disposed 197,369 · Balance 0 F12: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F13: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination. F19: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.

Filing footnotes · ownership attribution and instrument terms

F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2: 28,546 ordinary shares were returned to the reporting person's direct beneficial ownership on November 10, 2020 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 100,000 ordinary shares on October 23, 2018 and 161,635 ordinary shares were returned to the reporting person's direct beneficial ownership on November 11, 2020 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 250,000 ordinary shares on September 18, 2019.

F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination.

F5: These options vested on March 5, 2017.

F6: These options vested on March 4, 2018.

F7: These options vested on February 17, 2019.

F8: These options vested on March 3, 2020.

F9: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021.

F10: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination.

F11: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021.

F12: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.

F13: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination.

F14: 20,018 of these options vested on March 2, 2020, 20,017 will vest on March 2, 2021 and 20,018 will vest on March 2, 2022.

F15: Each RSU represents the right to receive one ordinary share of Mylan. 33,515 of the RSUs will vest on March 2, 2021 and 33,516 will vest on March 2, 2022.

F16: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.

F17: 28,291 of these options will vest on March 2, 2021 and 28,290 will vest on each of March 2, 2022 and March 2, 2023.

F18: Each RSU represents the right to receive one ordinary share of Mylan. 52,632 of the RSUs will vest on March 2, 2021, 52,631 will vest on March 2, 2022 and 52,632 will vest on March 2, 2023.

F19: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 02, 2021 Filed Mar 4, 2021 18:36 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	14,645	$0.00	$0.00	Disclosure SEC source: 0000899243-21-009943 · doc4.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 16, 2020 Filed Feb 12, 2021 18:00 UTC	Viatris Inc VTRS · Entity 3277	GiftCommon Stock	460,319	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006363 · doc5.xml · nonDerivative · entry 2 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Irrevocable Trust Disclosed balance after: 460,319 F1 · kind: This transaction involved a gift of securities by the reporting person to an irrevocable trust for the benefit of his spouse and children on December 16, 2020. The reporting person's spouse is the trustee of the trust. Read SEC document
December 16, 2020 Filed Feb 12, 2021 18:00 UTC	Viatris Inc VTRS · Entity 3277	GiftCommon Stock	460,319	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006363 · doc5.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction involved a gift of securities by the reporting person to an irrevocable trust for the benefit of his spouse and children on December 16, 2020. The reporting person's spouse is the trustee of the trust. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantRestricted Stock Units · Derivative	197,369	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 15 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,369 Underlying: Common Stock · 197,369 shares Expires not disclosed F11 · security: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021. F12 · price: Received in exchange for, and having substantially the same terms as (other than no longer being subject to the performance-based vesting conditions), performance restricted stock units of Mylan in connection with the Combination. F18 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2023. F18 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2023. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantRestricted Stock Units · Derivative	157,895	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 14 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,895 Underlying: Common Stock · 157,895 shares Expires not disclosed F9 · security: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. F10 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination. F17 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. 52,632 of the RSUs will vest on March 2, 2021, 52,631 will vest on March 2, 2022 and 52,632 will vest on March 2, 2023. F17 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. 52,632 of the RSUs will vest on March 2, 2021, 52,631 will vest on March 2, 2022 and 52,632 will vest on March 2, 2023. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantEmployee Stock Option - Right to Buy · Derivative	84,871	Not disclosed Strike: $17.48	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 13 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,871 Underlying: Common Stock · 84,871 shares Expires 2030-03-02 F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F16 · derivative.exercise_date: 28,291 of these options will vest on March 2, 2021 and 28,290 will vest on each of March 2, 2022 and March 2, 2023. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantRestricted Stock Units · Derivative	125,684	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 12 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,684 Underlying: Common Stock · 125,684 shares Expires not disclosed F11 · security: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021. F12 · price: Received in exchange for, and having substantially the same terms as (other than no longer being subject to the performance-based vesting conditions), performance restricted stock units of Mylan in connection with the Combination. F15 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2022. F15 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2022. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantRestricted Stock Units · Derivative	67,031	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 11 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,031 Underlying: Common Stock · 67,031 shares Expires not disclosed F9 · security: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. F10 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination. F14 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. 33,515 of the RSUs will vest on March 2, 2021 and 33,516 will vest on March 2, 2022. F14 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. 33,515 of the RSUs will vest on March 2, 2021 and 33,516 will vest on March 2, 2022. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantEmployee Stock Option - Right to Buy · Derivative	60,053	Not disclosed Strike: $27.45	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 10 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,053 Underlying: Common Stock · 60,053 shares Expires 2029-03-01 F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F13 · derivative.exercise_date: 20,018 of these options vested on March 2, 2020, 20,017 will vest on March 2, 2021 and 20,018 will vest on March 2, 2022. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantRestricted Stock Units · Derivative	73,225	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 9 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,225 Underlying: Common Stock · 73,225 shares Expires not disclosed F11 · security: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021. F12 · price: Received in exchange for, and having substantially the same terms as (other than no longer being subject to the performance-based vesting conditions), performance restricted stock units of Mylan in connection with the Combination. F11 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021. F11 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantRestricted Stock Units · Derivative	14,645	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 8 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,645 Underlying: Common Stock · 14,645 shares Expires not disclosed F9 · security: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. F10 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination. F11 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021. F11 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantEmployee Stock Option - Right to Buy · Derivative	71,600	Not disclosed Strike: $40.97	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 7 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,600 Underlying: Common Stock · 71,600 shares Expires 2028-03-02 F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F9 · derivative.exercise_date: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantEmployee Stock Option - Right to Buy · Derivative	65,574	Not disclosed Strike: $45.18	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 6 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,574 Underlying: Common Stock · 65,574 shares Expires 2027-03-03 F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F8 · derivative.exercise_date: These options vested on March 3, 2020. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantEmployee Stock Option - Right to Buy · Derivative	50,168	Not disclosed Strike: $46.27	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 5 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,168 Underlying: Common Stock · 50,168 shares Expires 2026-02-17 F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F7 · derivative.exercise_date: These options vested on February 17, 2019. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantEmployee Stock Option - Right to Buy · Derivative	41,637	Not disclosed Strike: $50.66	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 4 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,637 Underlying: Common Stock · 41,637 shares Expires 2025-11-17 F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F6 · derivative.exercise_date: These options vested on March 4, 2018. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantEmployee Stock Option - Right to Buy · Derivative	34,389	Not disclosed Strike: $55.84	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · derivative · entry 3 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,389 Underlying: Common Stock · 34,389 shares Expires 2024-03-05 F3 · security: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend. F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F5 · derivative.exercise_date: These options vested on March 5, 2017. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantCommon Stock	88,365	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · nonDerivative · entry 2 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Grantor Retained Annuity Trust Disclosed balance after: 88,365 F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:45 UTC	Viatris Inc VTRS · Entity 3277	GrantCommon Stock	459,699	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-031559 · doc4.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,319 F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F3 · balance_after: Includes 620 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerPerformance Restricted Stock Units · Derivative	197,369	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 18 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 197,369 shares Expires not disclosed F12 · security: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F13 · price: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination. F19 · derivative.exercise_date: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F19 · derivative.expiration_date: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	GrantPerformance Restricted Stock Units · Derivative	197,369	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 17 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,369 Underlying: Ordinary Shares · 197,369 shares Expires not disclosed F19 · derivative.exercise_date: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F19 · derivative.expiration_date: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerRestricted Stock Units · Derivative	157,895	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 16 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 157,895 shares Expires not disclosed F9 · security: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. F10 · price: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F18 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan. 52,632 of the RSUs will vest on March 2, 2021, 52,631 will vest on March 2, 2022 and 52,632 will vest on March 2, 2023. F18 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan. 52,632 of the RSUs will vest on March 2, 2021, 52,631 will vest on March 2, 2022 and 52,632 will vest on March 2, 2023. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerEmployee Stock Option - Right to Buy · Derivative	84,871	Not disclosed Strike: $17.48	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 15 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 84,871 shares Expires 2030-03-02 F3 · security: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F17 · derivative.exercise_date: 28,291 of these options will vest on March 2, 2021 and 28,290 will vest on each of March 2, 2022 and March 2, 2023. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerPerformance Restricted Stock Units · Derivative	125,684	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 14 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 125,684 shares Expires not disclosed F12 · security: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F13 · price: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination. F16 · derivative.exercise_date: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F16 · derivative.expiration_date: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	GrantPerformance Restricted Stock Units · Derivative	125,684	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 13 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,684 Underlying: Ordinary Shares · 125,684 shares Expires not disclosed F16 · derivative.exercise_date: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F16 · derivative.expiration_date: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerRestricted Stock Units · Derivative	67,031	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 12 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 67,031 shares Expires not disclosed F9 · security: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. F10 · price: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F15 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan. 33,515 of the RSUs will vest on March 2, 2021 and 33,516 will vest on March 2, 2022. F15 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan. 33,515 of the RSUs will vest on March 2, 2021 and 33,516 will vest on March 2, 2022. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerEmployee Stock Option - Right to Buy · Derivative	60,053	Not disclosed Strike: $27.45	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 11 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 60,053 shares Expires 2029-03-01 F3 · security: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F14 · derivative.exercise_date: 20,018 of these options vested on March 2, 2020, 20,017 will vest on March 2, 2021 and 20,018 will vest on March 2, 2022. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerPerformance Restricted Stock Units · Derivative	73,225	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 10 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 73,225 shares Expires not disclosed F12 · security: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F13 · price: Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination. F12 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F12 · derivative.expiration_date: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	GrantPerformance Restricted Stock Units · Derivative	73,225	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 9 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,225 Underlying: Ordinary Shares · 73,225 shares Expires not disclosed F12 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. F12 · derivative.expiration_date: Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerRestricted Stock Units · Derivative	14,645	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 8 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,645 shares Expires not disclosed F9 · security: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. F10 · price: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F11 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021. F11 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerEmployee Stock Option - Right to Buy · Derivative	71,600	Not disclosed Strike: $40.97	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 7 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 71,600 shares Expires 2028-03-02 F3 · security: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F9 · derivative.exercise_date: 23,867 of these options vested on March 2, 2019, 23,866 vested on March 2, 2020 and 23,867 will vest on March 2, 2021. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerEmployee Stock Option - Right to Buy · Derivative	65,574	Not disclosed Strike: $45.18	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 6 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 65,574 shares Expires 2027-03-03 F3 · security: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F8 · derivative.exercise_date: These options vested on March 3, 2020. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerEmployee Stock Option - Right to Buy · Derivative	50,168	Not disclosed Strike: $46.27	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 5 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 50,168 shares Expires 2026-02-17 F3 · security: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F7 · derivative.exercise_date: These options vested on February 17, 2019. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerEmployee Stock Option - Right to Buy · Derivative	41,637	Not disclosed Strike: $50.66	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 4 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 41,637 shares Expires 2025-11-17 F3 · security: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F6 · derivative.exercise_date: These options vested on March 4, 2018. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerEmployee Stock Option - Right to Buy · Derivative	34,389	Not disclosed Strike: $55.84	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · derivative · entry 3 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 34,389 shares Expires 2024-03-05 F3 · security: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. F4 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F5 · derivative.exercise_date: These options vested on March 5, 2017. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerOrdinary Shares	88,365	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · nonDerivative · entry 2 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Grantor Retained Annuity Trust Disclosed balance after: 0 F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F3 · price: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. Read SEC document
November 16, 2020 Filed Nov 18, 2020 19:18 UTC	Mylan II B.V. MYL · Entity 16217	Disposition to issuerOrdinary Shares	459,699	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-031506 · doc4.xml · nonDerivative · entry 1 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2 · shares: 28,546 ordinary shares were returned to the reporting person's direct beneficial ownership on November 10, 2020 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 100,000 ordinary shares on October 23, 2018 and 161,635 ordinary shares were returned to the reporting person's direct beneficial ownership on November 11, 2020 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 250,000 ordinary shares on September 18, 2019. F3 · price: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. Read SEC document
March 03, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionPerformance Restricted Stock Units · Derivative	30,988	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · derivative · entry 17 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,988 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Each PRSU represents the right to receive one ordinary share of Mylan N.V. The PRSUs were initially granted on March 3, 2017, subject to the attainment of previously established three-year performance goals and a vesting period. The PRSUs fully vested on March 3, 2020. F13 · derivative.expiration_date: Each PRSU represents the right to receive one ordinary share of Mylan N.V. The PRSUs were initially granted on March 3, 2017, subject to the attainment of previously established three-year performance goals and a vesting period. The PRSUs fully vested on March 3, 2020. Read SEC document
March 03, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	GrantPerformance Restricted Stock Units · Derivative	30,988	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · derivative · entry 16 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,988 Underlying: Ordinary Shares · 30,988 shares Expires not disclosed F13 · derivative.exercise_date: Each PRSU represents the right to receive one ordinary share of Mylan N.V. The PRSUs were initially granted on March 3, 2017, subject to the attainment of previously established three-year performance goals and a vesting period. The PRSUs fully vested on March 3, 2020. F13 · derivative.expiration_date: Each PRSU represents the right to receive one ordinary share of Mylan N.V. The PRSUs were initially granted on March 3, 2017, subject to the attainment of previously established three-year performance goals and a vesting period. The PRSUs fully vested on March 3, 2020. Read SEC document
March 03, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionRestricted Stock Units · Derivative	12,395	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · derivative · entry 15 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,395 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 12,395 of the RSUs granted on March 3, 2017 vested on each of March 3, 2018, March 3, 2019, and March 3, 2020. F12 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 12,395 of the RSUs granted on March 3, 2017 vested on each of March 3, 2018, March 3, 2019, and March 3, 2020. Read SEC document
March 03, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	Tax withholdingOrdinary Shares	13,677	$16.29	$222,798.33	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · nonDerivative · entry 8 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,518 F7 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the performance restricted stock units (PRSUs) granted on March 3, 2017. Read SEC document
March 03, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionOrdinary Shares	30,988	$0.00	$0.00	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · nonDerivative · entry 7 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 03, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	Tax withholdingOrdinary Shares	5,471	$16.29	$89,122.59	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · nonDerivative · entry 6 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,207 F6 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the RSUs granted on March 3, 2017. Read SEC document
March 03, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionOrdinary Shares	12,395	$0.00	$0.00	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · nonDerivative · entry 5 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 02, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionRestricted Stock Units · Derivative	33,516	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · derivative · entry 14 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,031 Underlying: Ordinary Shares · 33,516 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 33,516 of the RSUs granted on March 1, 2019 vested on March 2, 2020, 33,515 will vest on March 2, 2021, and 33,516 will vest on March 2, 2022. F11 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 33,516 of the RSUs granted on March 1, 2019 vested on March 2, 2020, 33,515 will vest on March 2, 2021, and 33,516 will vest on March 2, 2022. Read SEC document
March 02, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionRestricted Stock Units · Derivative	14,645	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · derivative · entry 13 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,645 Underlying: Ordinary Shares · 14,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 14,645 of the RSUs granted on March 2, 2018 vested on each of March 2, 2019 and March 2, 2020, and 14,645 will vest on March 2, 2021. F10 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 14,645 of the RSUs granted on March 2, 2018 vested on each of March 2, 2019 and March 2, 2020, and 14,645 will vest on March 2, 2021. Read SEC document
March 02, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	GrantRestricted Stock Units · Derivative	157,895	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · derivative · entry 12 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,895 Underlying: Ordinary Shares · 157,895 shares Expires not disclosed F9 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 52,632 of the RSUs will vest on March 2, 2021, 52,631 will vest on March 2, 2022 and 52,632 will vest on March 2, 2023. F9 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. 52,632 of the RSUs will vest on March 2, 2021, 52,631 will vest on March 2, 2022 and 52,632 will vest on March 2, 2023. Read SEC document
March 02, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	GrantEmployee Stock Option-Right to Buy · Derivative	84,871	$0.00 Strike: $17.48	$0.00	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · derivative · entry 11 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,871 Underlying: Ordinary Shares · 84,871 shares Expires 2030-03-02 F8 · derivative.exercise_date: 28,291 of the options will vest on March 2, 2021 and 28,290 will vest on each of March 2, 2022 and March 2, 2023. The options expire on March 2, 2030. Read SEC document
March 02, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	Tax withholdingOrdinary Shares	14,793	$17.48	$258,581.64	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · nonDerivative · entry 4 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,283 F5 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the RSUs granted on March 1, 2019. Read SEC document
March 02, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	Exercise / conversionOrdinary Shares	33,516	$0.00	$0.00	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · nonDerivative · entry 3 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 02, 2020 Filed Mar 4, 2020 18:41 UTC	Mylan II B.V. MYL · Entity 16217	Tax withholdingOrdinary Shares	6,464	$17.48	$112,990.72	Disclosure SEC source: 0000899243-20-007035 · doc4.xml · nonDerivative · entry 2 Malik Rajiv · CIK 0001388111 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,560 F4 · shares: Represents withholding of ordinary shares for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 2, 2018. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.